Note: Descriptions are shown in the official language in which they were submitted.
CA 03126333 2021-07-09
1
PcT/JP2020/000538
DESCRIPTION
PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL
ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES
TECHNICAL FIELD
[0001]
The present invention provides pharmaceuticals and
methods for intraocular or oral administration use for
preventing or treating a retinal disease (such as age-related
macular degeneration).
BACKGROUND ART
[0002]
Many retinal diseases, including retinitis pigmentosa
and age-related macular degeneration, have unknown causes,
and are intractable.
Humans obtain external information
through the five senses including vision, and in particular,
80% or more of the information is obtained from vision.
Accordingly, visual impairment due to intractable retinal
disease may reduce significantly the patient's quality of
life (QOL).
[0003]
Age-related macular degeneration (AMD) is known to be
a disease with high unmet medical needs in which treatment
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
2
PCT/JP2020/000538
satisfaction is low and contribution of drugs for the
treatment is low. Age-related macular degeneration is
roughly categorized based on pathogenic mechanism into two
types, the atrophic (dry) and the exudative (wet). In the
United States, among the age-related macular degeneration
patients, atrophic (dry) patients account for a large
proportion of about 85% to about 90%, while in Japan,
exudative (wet) patients accounts for a large proportion of
about 92%. However, effective therapeutic drugs for the
atrophic (dry) disease have not been known. Also, regarding
therapeutic drugs for the exudative (wet) type disease, only
anti-vascular endothelial growth factor (abbreviated: anti-
VEGF) drug by intravitreal injection administration has been
known. Moreover, therapeutic drugs effective for treating
or preventing of age-related macular degeneration, and
suppressing progression of the disease have not been
developed yet from substances having antioxidant property.
[0004]
So far, some compounds having therapeutic activity
against age-related macular degeneration have been reported,
and are under development. For example, according to the
patent document 1, Levodopa (another name, L-dopa (DOPA)),
which is known as a therapeutic drug for Parkinson's disease,
is reported to have a therapeutic activity against age-
related macular degeneration.
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
3
PCT/JP2020/000538
[0005]
Aso, many of the compounds under development as
therapeutic drugs for age-related macular degeneration,
including the above-mentioned anti-VEGF drug, are
administered by an intravitreal injection administration.
Also, although some cases by an administration through a
local route or an oral administration have been reported,
the dose thereof is not low. Accordingly, it is desired to
develop an eye drop that can be suppressed its administration
dose and also can be easily administered.
{00061
As the characteristics of the mechanism of the above-
mentioned onset of the atrophic (dry) type of age-related
macular degeneration, an event where an inflammation is
occurred on retinal pigment epithelium cells (RPE cells) and
thereby some photoreceptor cells are lost, so-called cell
death is known as one of the causes. Here a retina is rich
in unsaturated fatty acids (Non-patent document 1), and eyes
are constantly exposed to light, and are known to consume a
large amount of oxygen (Non-patent document 2). Accordngly,
since it can be said that the retina is in an environment
susceptible to oxidative damage, it can be expected to lead
to unprecedented therapeutic drugs by developing
antioxidative therapeutic drugs.
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
4
PCT/JP2020/000538
CITATION LIST
PATENT DOCUMENT
[0007]
Patent Document 1: JP 2011-520788 Al
NON-PATENT DOCUMENT
[0008]
Non-Patent Document 1: Acar, N. et al., PLosS. One.,
2012, 7, 35102
Non-Patent Document 2: Ye.X. et al., Trends. Mol. Med.,
2010, 16, 417-25
SUMMARY OF INVENTION
(PROBLEMS TO BE SOLVED BY INVENTION)
[0009)
The present invention provides pharmaceuticals and
methods for use of intraocular administration (including eye
drop, and eye ointment) or oral administration, for
preventing or treating age-related macular degeneration, or
suppressing a progression of the disease, by using certain
compounds having antioxidative properties, in particular
anti-lipid peroxidative properties.
(MEANS TO SOLVE PROBLEMS)
[0010]
The inventors found out that a pharmaceutical
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
composition for use of intraocular administration (including
eye drop, and eye ointment) or oral administration, the
pharmaceutical composition comprising an effective amount of
certain compounds and pharmaceutically acceptable carriers
5 is useful for preventing or treating retinal diseases (such
as age-related macular degeneration), or suppressing a
progression of the disease.
[0011]
That is, the present invention provides the following
embodiments, but are not limited thereto.
[0012]
(Pharmaceutical Composition)
[1] A pharmaceutical composition for intraocular
administration or oral administration, for preventing or
treating a retinal disease, or suppressing a progression of
the disease in a subject in need of treatment, the
composition comprising an effective amount of one or more
compounds selected from the following group, and a
pharmaceutically acceptable carrier,
a group consisting of apomorphine ((R)-(-)-apomorphine
hydrochloride), eseroline ((-)-eseroline
fumarate),
ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
4-(4-methy1-1-piperaziny1)-10H-thieno[2,3-
b] [1,5]benzodiazepine, methyl 3-amino-4-
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
6
PCT/JP2020/000538
(phenylamino)benzoate, methyl 3-
amino-4-((4-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-((3-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-
(benzylamino)benzoate, methyl 3-
amino-4-((1-
phenylethyl)amino)benzoate, 1-(4-
(trifluoromethoxy)phenyl)indolin-5-amine, 1-
(3,5-
dimethylpheny1)-1H-indo1-6-amine, 1-
(3,5-
dimethylphenyl)indolin-6-amine, 1-(4-
methoxypheny1)-1H-
indo1-6-amine, 1-(4-
(methylthio)pheny1)-1H-indo1-6-amine,
1-(4-(trifluoromethoxy)pheny1)-1H-indo1-5-amine, and
indapamide (4-
chloro-N-[(2RS)-2-methy1-2,3-dihydro-1H-
indo1-1-y1]-3-sulfamoyl benzamide).
[2] The pharmaceutical composition according to [1] wherein
the compound is one or more compounds selected from the group
consisting of the following group,
a group consisting of apomorphine ((R)-(-)-apomorphine
hydrochloride), eseroline ((-)-eseroline
fumarate),
ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
4-(4-methyl-l-piperaziny1)-10H-thieno[2,3-
b][1,5]benzodiazepine, and indapamide (4-chloro-N-[(2RS)-2-
methy1-2,3-dihydro-1H-indo1-1-y1]-3-sulfamoyl benzamide).
[2-2] The
pharmaceutical composition according to [1] or
[2] wherein the compound is one or more compounds selected
from the group consisting of the following group,
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
7
PCT/JP2020/000538
a group consisting of ethoxyquin (6-ethoxy-2,2,4-
trimethy1-1,2-dihydroquinoline), and methyldopa (methyldopa
sesquihydrate).
[3] The pharmaceutical composition according to [1] or [2]
wherein the retinal disease is one or more disease selected
from the group consisting of diabetic retinopathy, retinitis
pigmentosa, Stargardt disease, hypertensive retinopathy,
glaucoma, cataract, central retinal artery occlusion,
polypoidal choroidal vasculopathy, Leber congenital
amaurosis (LCA), Usher syndrome, choroideremia, rod-cone or
cone-rod dystrophy, ciliary disorder, mitochondrial disease,
progressive retinal atrophy, geographic atrophy, familial or
acquired macular degeneration, retinal photoreceptor disease,
disease on retinal pigment epithelium, cystoid macular edema,
retinal degenerative disease, vitreous opacity, uveitis,
retinal detachment, traumatic retinal damage, iatrogenic
retinal injury, macular hole, macular telangiectasia,
ganglion cell disease, optic nerve cell disease, optic
neuropathy, ischemic retinal disease, retinopathy of
prematurity, retinal vascular occlusion, familial
macroaneurysm, retial vascular disease, ocular vascular
disease, vascular disease, and ischemic optic neuropathy.
[4] The pharmaceutical composition according to any one of
[1] to [3] wherein the retinal disease is an age-related
macular degeneration.
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
8
PCT/JP2020/000538
[5] The pharmaceutical composition according to any one of
[1] to [4] wherein the age-related macular degeneration is
atrophic (dry) age-related macular degeneration.
[6] The pharmaceutical composition according to any one of
[1] to [4] wherein the age-related macular degeneration is
exudative (wet) age-related macular degeneration.
[7] The pharmaceutical composition according to any one of
[1] to [6] which is formulated into eye drop or eye ointment.
[7-2] The pharmaceutical composition according to any
one of [1] to [6] which is formulated into eye drop, eye
ointment, eye gel, eye cream, tablet, fine granule, or
capsule.
[8] The pharmaceutical composition according to any one of
[11 to [7] wherein an effective dose of the compound is a
low dose of about one-fifth or less of the half-lethal dose
of each compound.
[8-2] The pharmaceutical composition according to any
one of [1] to [7] wherein an effective dose of the compound
is a low dose of about one-tenth or less of the half-lethal
dose of each compound.
[8-3] The pharmaceutical composition according to any
one of [1] to [7] wherein an effective dose of the compound
is a low dose of about one-twentyth or less of the half-
lethal dose of each compound.
[8-4] The pharmaceutical composition according to any
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
9
PCT/JP2020/000538
one of [1] to [7] wherein an effective dose of the compound
is a low dose of about one-fiftyth or less of the half-lethal
dose of each compound.
[9] The phaimaceutical composition according to any one of
[1] to [8] wherein an effective dose of the compound is about
five(5) weight % or less based on the weight of the
pharmaceutical composition for intraocular administration,
and is about eighty(80) weight t or less based on the weight
of the pharmaceutical composition for oral administration.
[9-2] The
pharmaceutical composition according to any
one of [1] to [8] wherein an effective dose of the compound
is about three(3) weight t or less based on the weight of
the pharmaceutical composition for
intraocular
administration, and is about fifty(50) weight t or less based
on the weight of the pharmaceutical composition for oral
administration.
[9-3] The
pharmaceutical composition according to any
one of Di to [8] wherein an effective dose of the compound
is about one(1)weight % or less based on the weight of the
pharmaceutical composition for intraocular administration.
[9-4] The
pharmaceutical composition according to any
one of [1] to [8] wherein an effective dose of the compound
is about zero point five(0.5)weight % or less based on the
weight of the pharmaceutical composition for intraocular
administration.
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
[0013]
(Eye Drop)
[101An eye drop for preventing or treating a retinal disease,
or suppressing a progression of the disease in a subject in
5 need of treatment, the eye drop comprising an effective
amount of one or more compounds selected from the following
group, and a pharmaceutically acceptable carrier,
a group consisting of apomorphine ((R)-(-)-apomorphine
hydrochloride), eseroline ((-)-eseroline
fumarate),
10 ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
4-(4-methy1-1-piperaziny1)-10H-thieno[2,3-
b] [1,5]benzodiazepine, methyl 3-
amino-4-
(phenylamino)benzoate, methyl 3-
amino-4-((4-
methoxyphenyl)amino)benzoate, methyl 3-amino-4-((3-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-
(benzylamino)benzoate, methyl 3-
amino-4-((1-
phenylethyl)amino)benzoate, 1-(4-
(trifluoromethoxy)phenyl)indolin-5-amine, 1-
(3,5-
dimethylpheny1)-1H-indo1-6-amine, 1-(3,5-
dimethylphenyl)indolin-6-amine, 1-(4-
methoxypheny1)-1H-
indo1-6-amine, 1-(4-(methylthio)pheny1)-1H-indo1-6-amine,
1-(4-(trifluoromethoxy)pheny1)-1H-indo1-5-amine, and
indapamide (4-
chloro-N-[(2RS)-2-methy1-2,3-dihydro-1H-
indo1-1-y1]-3-sulfamoyl benzamide).
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
11
PCT/JP2020/000538
[10-2] The
eye drop according to [10] wherein the compound
is one or more compounds selected from the group consisting
of the following group,
a group consisting of apomorphine ((R)-(-)-apomorphine
hydrochloride), eseroline ((-)-eseroline fumarate),
ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
4-(4-methyl-l-piperaziny1)-10H-thieno[2,3-
b][1,5]benzodiazepine, and indapamide (4-chloro-N-[(2RS)-2-
methyl-2,3-dihydro-1H-indo1-1-y1]-3-sulfamoyl benzamide).
[10-3] The
eye drop according to [10] wherein the compound
is one or more compounds selected from the group consisting
of the following group,
a group consisting of ethoxyquin (6-ethoxy-2,2,4-
trimethy1-1,2-dihydroquinoline), and methyldopa (methyldopa
sesquihydrate).
[10-4] The
eye drop according to 10] which is a
sterilized type of unit dosage form not containing a
preservative.
[10-5] The eye drop
according to [10] which does not
substantially contain benzalkonium chloride.
[0014]
(Oral Drug)
[11] An oral drug for preventing or treating a retinal
disease, or suppressing a progression of the disease in a
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
12
PCT/JP2020/000538,
subject in need of treatment, the oral drug comprising an
effective amount of one or more compounds selected from the
following group, and a pharmaceutically acceptable carrier,
a group consisting of apomorphine ((R)-(-)-apomorphine
hydrochloride), eseroline ((-)-eseroline fumarate),
ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
4-(4-methyl-l-piperaziny1)-10H-thieno[2,3-
b] [1,5]benzodiazepine, methyl 3-
amino-4-
(phenylamino)benzoate, methyl 3-amino-4-((4-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-((3-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-
(benzylamino)benzoate, methyl 3-
amino-4-((1-
phenylethyl)amino)benzoate, 1-(4-
(trifluoromethoxy)phenyl)indolin-5-amine,
dimethylpheny1)-1H-indo1-6-amine, 1-
(3,5-
dimethylphenyl)indolin-6-amine, 1-(4-
methoxypheny1)-1H-
indo1-6-amine, 1-(4-
(methylthio)pheny1)-1H-indo1-6-amine,
1-(4-(trifluoromethoxy)pheny1)-1H-indo1-5-amine, and
indapamide (4-chloro-N-
[(2RS)-2-methy1-2,3-dihydro-1H-
indo1-1-y1]-3-sulfamoyl benzamide).
[11-2] The
oral drug according to [11] wherein the
compound is one or more compounds selected from the group
consisting of the following group,
a group consisting of apomoLphine ((R)-(-)-apomorphine
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
13
PCT/JP2020/000538
hydrochloride), eseroline ((-)-eseroline
fumarate),
ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
4-(4-methyl-l-piperaziny1)-10H-thieno[2,3-
b] [1,5]benzodiazepine, and indapamide (4-chloro-N-1(2R5)-2-
methy1-2,3-dihydro-1H-indo1-1-y11-3-sulfamoy1 benzamide).
[11-3] The
oral drug according to [11] wherein the
compound is one or more compounds selected from the group
consisting of the following group,
a group consisting of ethoxyquin (6-ethoxy-2,2,4-
trimethy1-1,2-dihydroquinoline), and methyldopa (methyldopa
sesquihydrate).
[0015]
(Use)
[12] Use of one or more compounds selected from the following
group in preparation of a pharmaceutical for intraocular
administration or oral administration for preventing or
treating a retinal disease, or suppressing a progression of
the disease in a subject in need of treatment,
a group consisting of apomorphine ((R)-(-)-apomorphine
hydrochloride), eseroline ((-)-eseroline
fumarate),
ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
4-(4-methyl-1-piperaziny1)-10H-thieno[2,3-
b] [1,5]benzodiazepine, methyl 3-amino-4-
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
14
PCT/JP2020/000538
(phenylamino)benzoate, methyl 3-
amino-4-((4-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-((3-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-
(benzylamino)benzoate, methyl 3-
amino-4-((1-
phenylethyl)amino)benzoate, 1-(4-
(trifluoromethoxy)phenyl)indolin-5-amine, 1-
(3,5-
dimethylpheny1)-1H-indo1-6-amine, 1-
(3,5-
dimethylphenyl)indolin-6-amine, 1-(4-
methoxypheny1)-1H-
indo1-6-amine, 1-(4-
(methylthio)pheny1)-1H-indo1-6-amine,
1-(4-(trifluoromethoxy)pheny1)-1H-indo1-5-amine, and
indapamide (4-
chloro-N-P2RS)-2-methyl-2,3-dihydro-1H-
indo1-1-y11-3-sulfamoyl benzamide).
[12-2] The
use according to [12] wherein the compound is
one or more compounds selected from the group consisting of
the following group,
a group consisting of apomorphine ((R)-(-)-apomorphine
hydrochloride), eseroline ((-)-eseroline
fumarate),
ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
4-(4-methy1-1-piperaziny1)-10H-thieno[2,3-
bl [1,5]benzodiazepine, and indapamide (4-chloro-N-P2RS)-2-
methy1-2,3-dihydro-1H-indol-1-y1]-3-sulfamoyl benzamide).
[12-3] The
use according to [12] wherein the compound is
one or more compounds selected from the group consisting of
the following group,
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
a group consisting of ethoxyquin (6-ethoxy-2,2,4-
trimethy1-1,2-dihydroquinoline), and methyldopa (methyldopa
sesquihydrate).
[0016]
5 (Method)
[13] A method for preventing or treating a retinal disease,
or suppressing a progression of the disease in a subject in
need of treatment, which comprises administering an
effective amount of one or more compounds selected from the
10 following
group to a subject in need of treatment, a group
consisting of apomorphine ((R)-
(-)-apomorphine
hydrochloride), eseroline ((-)-eseroline
fumarate),
ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
15 4-(4-methyl-l-piperaziny1)-10H-thieno[2,3-
b] [1,5]benzodiazepine, methyl 3-
amino-4-
(phenylamino)benzoate, methyl 3-
amino-4-((4-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-((3-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-
(benzylamino)benzoate, methyl 3-amino-4-((1-
phenylethyl)amino)benzoate, 1-(4-
(trifluoromethoxy)phenyl)indolin-5-amine, 1-
(3,5-
dimethylpheny1)-1H-indo1-6-amine, 1-
(3,5-
dimethylphenyl)indolin-6-amine, 1-(4-
methoxypheny1)-1H-
indo1-6-amine, 1-(4-(methylthio)pheny1)-1H-indo1-6-amine,
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
16
PCT/JP2020/000538
1-(4-(trifluoromethoxy)pheny1)-1H-indo1-5-amine, and
indapamide (4-
chloro-N-f(2RS)-2-methy1-2,3-dihydro-1H-
indo1-1-y1]-3-sulfamoyl benzamide).
113-21 The
method according to [13] wherein the compound
is one or more compounds selected from the group consisting
of the following group,
a group consisting of apomorphine ((R)-(-)-apomorphine
hydrochloride), eseroline ((-)-eseroline
fumarate),
ethoxyquin (6-ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa (methyldopa sesquihydrate), olanzapine (2-methyl-
4-(4-methy1-1-piperaziny1)-10H-thieno[2,3-
b] [1,5]benzodiazepine, and indapamide (4-chloro-N-[(2RS)-2-
methy1-2,3-dihydro-1H-indo1-1-y1]-3-sulfamoyl benzamide).
[13-3] The
method according to [13] wherein the compound
is one or more compounds selected from the group consisting
of the following group,
a group consisting of ethoxyquin (6-ethoxy-2,2,4-
trimethy1-1,2-dihydroquinoline), and methyldopa (methyldopa
sesquihydrate).
[0017]
(Others)
[14] The pharmaceutical composition according to [1], the
eye drop according to [10], or the oral drug according to
[11], which further comprises one or more compounds for
increasing an efficacy of the pharmaceutical composition,
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
17
PCT/JP2020/000538
the eye drop, or the oral drug.
[14-1] The
pharmaceutical composition according to [1],
the eye drop according to [10], or the oral drug according
to [11], wherein the one or more compounds for increasing an
efficacy of the pharmaceutical composition, the eye drop, or
the oral drug is antibiotic, steroid, anti-inflammatory
agent, analgesic, surfactant, chelating agent, buffering
agent, pH adjusting agent, or adjuvant, or any combinations
of two or more of these compounds.
[14-2] The
pharmaceutical composition according to [1],
the eye drop according to [10], or the oral drug according
to [11], wherein the one or more compounds for increasing an
efficacy of the pharmaceutical composition, the eye drop, or
the oral drug is vitamin C source, vitamin E source, vitamin
A source, beta-carotene, zinc source, or copper source, or
any combinations of two or more of these compounds.
[15] The pharmaceutical composition according to [1], the
eye drop according to [10], or the oral drug according to
[11], wherein the subject in need of treatment is a mammalian.
[15-2] The
pharmaceutical composition according to [1],
the eye drop according to [10], or the oral drug according
to [11], wherein the subject in need of treatment is a human.
[15-3] The
pharmaceutical composition according to [1],
the eye drop according to [10], or the oral drug according
to [11], wherein the subject in need of treatment is a human
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
18
PCT/JP2020/000538
having 60 or more ages.
[15-4] The
pharmaceutical composition according to [1],
the eye drop according to [10], or the oral drug according
to (111, the use according to [12], or the method according
to [13], wherein the subject in need of treatment is a human
containing some Drusen deposits.
[15-5] The
pharmaceutical composition according to [1],
the eye drop according to [10], or the oral drug according
to [11], the use according to [12], or the method according
to [13], wherein the subject in need of treatment is white
race.
[16] The pharmaceutical composition according to [1], the
eye drop according to [10], or the oral drug according to
[11], for use to prevent or treat a retinal disease, or
suppress a progression of the disease in a subject in need
of treatment.
[17] A food or beverage for preventing or treating a retinal
disease, or suppressing a progression of the disease, the
food or beverage comprising the above-mentioned compound
according to [1].
[18] The food or beverage according to [17], which is a
health food, a functional food, a food for specified health
uses, a nutritional supplement, a food with a label of
Reduction of Disease Risk Claims, or a food for the sick.
[19] A method for preventing or treating a disease due to an
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
19
PCT/JP2020/000538
activation of glial cell of retina (for example, muller cell,
microglia), or suppressing a progression of the disease,
comprising administering a therapeutically effective amount
of the above-mentioned compound according to [1].
[20] A method for preventing or treating a disease due to an
increased expression amount of specific gene (for example,
mRNA of marker protein) which exists in glial cell of retina
(for example, muller cell, microglia), or suppressing a
progression of the disease, comprising administering a
therapeutically effective amount of the above-mentioned
compound according to [1].
[21] A method for preventing or treating a disease due to an
activity of a pathway of a complement, or suppressing a
progression of the disease, which comprises administering a
therapeutically effective amount of the above-mentioned
compound according to [1].
[22] A method for preventing or treating a disease due to an
increased expression amount of mRNA of speciifc complement,
or suppressing a progression of the disease, comprising
administering a therapeutically effective amount of the
above-mentioned compound according to [1].
[Effect]
[0018]
The pharmaceutical composition of the present invention
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
for intraocular or oral admnistration comprising specifc
compound having anti-lipid peroxidation property is useful
for preventing or treating a retinal disease, for example,
age-related macular degeneration (in particular, atrophic
5 (dry) of age-related macular degeneration), or suppresing a
progression of the disease.
BRIEF DESCRIPTION OF DRAWINGS
[0019]
10 [Figure 1] Figure 1
is charts showing a method for
producing age-related macular degeneration (AMD) model mice
(production schedule) in the case of oral administration.
(a) AND model mouse production schedule; (b) ONL measurement
method in which ONL thickness was measured over 27 points
15 (A-center-Z) every 180 pm (left: observation field of 4 times,
right: observation field of 60 times).
[Figure 2]
Figure 2 (A) is charts showing the results of
evaluating the thickness of an outer nuclear layer (ONL) in
the case of oral administration, and also showing ONL bright
20 field
image (observation magnification: 60 times) in the
case of the dose of 50 pmol/kg of the present compounds
(ethoxyquin (Compound X), eseroline (Compound W), methyldopa
(Compound Y), and indapamide (Compound A)) compared to
Control or control comound (edaravone, OT-551). Figure 2
(B) is charts showing the results of evaluating the thickness
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
21
POT/JP2020/000538
of an outer nuclear layer (ONL) in the case of oral
administration, and also showing mean thickness of an outer
nuclear layer (ONL) (Mean S.D.,
(n=3-5), mean+S.D.,
"p<0.01 v.s. cotrol, ## p<0.01 v.s. Light).
Figure 2 (C)
is charts showing the results of evaluating the thickness of
an outer nuclear layer (ONL) in the case of oral
administration, and also showing ONL bright field image
(observation magnification: 40 times) in the case of the
dose of 100 pmol/kg or 200 pmol/kg of the present compounds
(methyldopa (Compound Y)) compared to Control. Figure 2 (D)
is is charts showing the results of evaluating the thickness
of an outer nuclear layer (ONL) in the case of oral
administration, and also showing mean thickness of an outer
nuclear layer (ONL) (n=4, ¨p<0.01 v.s. ctrl, ## p<0.01 v.s.
light).
[Figure 3]
Figure 3 is charts showing a method for
producing age-related macular degeneration (AMD) model mice
(production schedule) in the case of administration with eye
drop.
[Figure 4] Figure 4 (A) is
charts showing the results of
evaluating the thickness of an outer nuclear layer (ONL) in
the case of administration with the eye drop of 0.45 %,
0.75 % or 1 % concentration of methyldopa and also showing
ONL bright field image (observation magnificantion: 40
times) in the case of administration of 0.45 %, 0.75 % or
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
22
PCT/3P2020/000538
1 % concentration with the eye drop of the present compound
(methyldopa (Compound Y)) compared to Control. Figure 4 (B)
is charts showing the results of evaluating the thickness of
an outer nuclear layer (ONL) in the case of oral
administration, and also showing mean thickness of ONL of
the present compound (methyldopa (Compound Y)) compared to
Control (n=3, **p<0.01 v.s. ctrl, ## p<0.01 v.s. light).
[Figure 5]
Figure 5 is a table summarizing main
action/action points, half-lethal dose (LD50 and animal
administration examples for the activity indicator compound
and the present compound. The LD50 was shown for edaravone
and the four compounds used in this study. Here,
oral
represents oral administration, p.o. represents per os (oral
administration), and i.p. represents intraperitoneal
injection.
[Figure 6]
Figure 6 is charts showing the results of
activity evaluation test of Muller cell. Figure 6 (A) is
charts showing a change of expression amounts of mRNA of
muller cell marker protein in a normal group of mice and a
pathological group of mice in the case of not administrating
with any test compound. Also Figure 6 (B) is charts showing
a change of expression amounts of mRNA of muller cell marker
protein in a normal group of mice, a pathological group of
mice in the case of not administrating with any test compound,
and a pathological group of mice in the case of
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
23
PCT/JP2020/000538
administrating with any test compound.
[Figure 7]
Figure 7 is charts showing the results of
activity evaluation test of microglia.
Figure 7 (A) is
charts showing a change of expression amounts of mRNA of
microglia marker protein in a normal group of mice and a
pathological group of mice in the case of not administrating
with any test compound. Also Figure 7 (B) is charts showing
a change of expression amounts of mRNA of microglia marker
protein in a normal group of mice, a pathological group of
mice in the case of not administrating with any test compound,
and a pathological group of mice in the case of
administrating with any test compound.
[Figure 8]
Figure 8 is charts showing the results of
activity evaluation test of the complement.
Figure 8 (A) is charts showing a change of expression amounts
of mRNA of the complement in a normal group of mice and a
pathological group of mice in the case of not administrating
with any test compound. Also, Figure 8 (B) is charts showing
a change of expression amounts of mRNA of the complement in
a normal group of mice, a pathological group of mice in the
case of not administrating with any test compound, and a
pathological group of mice in the case of administrating
with any test compound.
MODE FOR CARRYING OUT THE INVENTION
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
24
PCT/JP2020/000538
[0020]
(Pharmaceutical Use)
The term of "retinal disease" represents diseases and
disorders in retina, and specific examples thereof include
one or more diseases selected from the group consisting of
diabetic retinopathy, retinitis pigmentosa , Stargardt
disease, hypertensive retinopathy, glaucoma, cataract,
central retinal artery occlusion, polypoidal choroidal
vasculopathy, Leber congenital amaurosis (LCA), Uscher
syndrome, choroideremia, rod-cone or cone-rod dystrophy,
ciliary disorder, mitochondrial diseases, progressive
retinal atrophy, geographic atrophy, familial or acquired
macular degeneration, retinal photoreceptor disease,
diseases due to retinal pigment epithelium, cystoid macular
edema, retinal degenerative disease, vitreous opacity,
uveitis, retinal detachment, traumatic retinal damage,
iatrogenic retinal injury, macular hole, macular
telangiectasia, ganglion cell disease, optic nerve cell
disease, optic neuropathy, ischemic retinal disease,
retinopathy of prematurity, retinal vascular occlusion,
familial macroaneurysm, retial vascular disease, ocular
vascular disease, ocular vascular disease, or ischemic optic
neuropathy. Preferred specific examples thereof include
diabetic retinopathy, retinitis pigmentosa, and age-related
macular degeneration.
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
[0021]
The term of "age-related macular degeneration (AND)"
represents an aging-related disease causing a vidual loss of
macula (center of field of view) due to a damage of retina.
5 The age-
related macular degeneration is started from Drusen
(yellow deposits) in macula between retinal pigment
epithelium and choroid under its epithelium. The subjects
containing a drusen may develop following the symptom to
those having age-related macular degeneration.
10 Examples
of the age-related macular degeneration
include atrophic (dry) type of disease and exudative (wet)
type of disease, which are generally known. The development
of the geographic atrophy may be observed as the
characteristics of the atrophic (dry) type of age-related
15 macular
degeneration, while the development of angiogenesis
may be observed as the characteristics of the exudative type
of macular degeneration degeneration.
The age-related macular degeneration used herein
encompasses related symptoms of age-related macular
20
degeneration. Examples of the related symptoms include one
or more symptoms including a blur due to distortion of the
retina in center field of view (metamorphopsia); a loss of
central area (central scotoma) and a reduction of overall
eyesight (poor eyesight), due to a disorder of retina; a
25
difficulty in distinguising a certain colour and another
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
26
PCT/JP2020/000538
colour (color blindness); an obstruction of retinal pigment
epithelium (RPE) (including aggregation and/or loss of
pigment); RPE detachment; geographic atrophy; a subretinal
neovascularization, a disc-shaped scar, and astigmatism
(deformed vision), and aren't limited thereto.
[00221
As glial cells existed in a retina, a Muller cell,
microglia or the others are known. When
the retina is
subjected to a lipid peroxidation, a Muller cell or micrglia
as glial cell is activated. It has been
presumed that
inflammatory substances are secreted from the activated
glial cells, and the complement pathway which is accompanied
by the phenomenon is activated, and finally, cell dealth
(deterioration of pathology) may be caused. Also, it is
known that these glial cells are activated in retinal
diseases (such as age-related macular degeneration), and an
expression amount of marker protein by activation of the
glial cells are increased in a pathological group.
Accordingly, the suppression of the expression amount of
these proteins can be used as an indicator for examining an
effectiveness of a certain compound against a treatment,
prevention or suppression of retinal diseases (such as age-
related macular degeration).
[00231
In an experiment for analysis of glial cell activation
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
27
PCT/JP2020/000538
of the present invention, a real-time PCR method may be used,
but is not be limited to this method. Here the real-tme PCR
method represents a method for monitoring the PCR
amplification amounts in real-time and then analysing them.
Specific examples of the real-time PCR method include
generally-known methods, and may be carried out by using
commercially available reagents (such as a primer, and a
fluorescent substance) and devices.
[0024]
As used herein, the "treatment or treating" or
"prevention or preventing" or "suppression or suppressing of
a progression" against retinal disease encompasses at least
one of the followings. (1) excluding the above-mentioned
retinal disease, for example, one or more of the above-
mentioned specific diseases, typically the AMD disease, and
one or more of the relevant symptoms; (2) reducing or
minimizing the degree of seriousness of the above-mentioned
retinal disease, for example, one or more of the above-
mentioned specific diseases, typically the AMD disease and
one or more of the relevant symptoms: (3) delaying the
progression or the onset of the above-mentioned retinal
disease, for example, one or more of the above-mentioned
specific diseases, typically, the AMD disease and one or
more of the relevant symptoms; and (4) lowering, minimizing
or excluding an incidence or a frequency of the above-
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
28
PCT/3P2020/000538
mentioned retinal disease, for example, one or more of the
above-mentioned specific diseases, typically, AND disease
and one or more of the relevant symptoms.
[0025]
The "subject" for the purpose of the treatment and so
on used herein represents mammalian, and includes human or
non-human animals, and preferably includes human. The
subject encompasses human of ages of 60 ages or more
(preferably 65 ages or more, and more preferably 70 ages or
more), and also preferably human containing Drusen deposits.
For example, the white race which is sensitive to the
atrophic (dry) type of disease is more preferaly included.
[0026]
The present invention provides a phaLmaceutical
composition as an intraocular administration use (including
eye drop, and eye ointment) or an oral administration use,
for preventing or treating retinal diseases, or suppressing
a progression of the diseases in a subject in need of the
treatment and so on, the composition comprising as an active
drug a therapeutically effective amount of one or more of
the compounds selected from the following group (hereinafter,
the compound may be referred to as "active drug of the
present invention", or "present compound") and a
pharmaceutically acceptable carrier (hereinafter, the
pharmaceutical composition may be referred to as
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
29
PCT/JP2020/000538
"pharmaceutical composition of the present invention" or
"present pharmaceutical composition").
Examples of the
active drug include the following groups: a group consisting
of apomorphine ((R)-(-)-apomorphine
hydrochloride),
eseroline ((-)-eseroline fumarate), ethoxyquin (6-ethoxy-
2,2,4-trimethy1-1,2-dihydroquinoline),
methyldopa
(methyldopa sesquihydrate), olanzapine (2-methy1-4-(4-
methyl-l-piperaziny1)-10H-thieno[2,3-b] [1,5]benzodiazepine,
methyl 3-amino-4-(phenylamino)benzoate, methyl 3-amino-4-
((4-methoxyphenyl)amino)benzoate, methyl 3-amino-4-((3-
methoxyphenyl)amino)benzoate, methyl 3-
amino-4-
(benzylamino)benzoate, methyl 3-
amino-4-((1-
phenylethyl)amino)benzoate, 1-(4-
(trifluoromethoxy)phenyl)indolin-5-amine, 1-
(3,5-
dimethylpheny1)-1H-indo1-6-amine, 1-(3,5-
dimethylphenyl)indolin-6-amine, 1-(4-
methoxypheny1)-1H-
indo1-6-amine, 1-(4-
(methylthio)pheny1)-1H-indol-6-amine1
1-(4-(trifluoromethoxy)pheny1)-1H-indo1-5-amine, and
indapamide (4-
chloro-N-[(2RS)-2-methy1-2,3-dihydro-1H-
indo1-1-y1]-3-sulfamoyl benzamide).
[0027]
Here, the compounds which are included in the above-
mentioned compound group are compounds which are found to
show any permeability of the blood-brain barrier, and also
a lipid peroxidation suppression effect in PCT/JP
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
2018/025496 filed by the inventors and so on of the present
application. The structural formulae of these compounds are
indicated below.
Apomorphine: ((R)-(-)-Apomorphine hydrochloride):
HO
HO
N
Eseroline: ((-)-Eseroline fumarate):
HO
NH
OH
0
0
10 Ethoxyquin: (6-
Ethoxy-2,2,4-trimethy1-1,2-
dihydroquinoline):
Methyldopa: (Methyldopa sesquihydrates):
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
31
PCT/JP2020/000538
COOH
4115 N H2
HO
OH =11/2 1120
Olanzapine: (2-Methyl-4-(4-methy1-1-piperaziny1)-10H-
thieno[2,3-b1 11,5)benzodiazepine):
H S
\--N
Methyl 3-amino-4-(phenylamino)benzoate:
' I
N
HN,N
S
HN
CI
Methyl 3-amino-4-(benzylamino)benzoate:
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
32
PCT/JP2020/000538
0
HN
0
H2N
,
Methyl 3-amino-4-((l-phenylethyl)aminc)benzoate:
HN
0
H2N
0,...1
I
,
1-(4-(Trifluoromethoxy)pheny1)-1H-indo1-5-amine:
H2N
N
F--X0
F F
,
1-(3,5-Dimethylpheny1)-1H-indo1-6-amine:
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
33
PCT/JP2020/000538
\
H2N N
,
1-(3,5-Dimethylphenyl)indo1in-6-amine:
H2N N
,
1-(4-Methoxypheny1)-1H-indo1-6-amine:
H2N
\
N
,
1-(4-(Methylthio)pheny1)-1H-indo1-6-amine:
H2N
\
N
S
.,
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
34
PCT/JP2020/000538
,
1-(4-(Trifluoromethoxy)pheny1)-1H-indo1-5-amine:
H2N
\
N
F
0F
F
,
Indapamide: (4-Chloro-N-P2RS)-
2-methy1-2,3-dihydro-
1H-indo1-1-y13-3-sulfamoyl benzamide):
CI
H
S
0 0 0
The present compound as active drug includes the forms
of the above-mentioned compounds and pharmaceutically
acceptable salts thereof. Also,
the active drug of the
present invention or a pharmaceutically acceptable salt
thereof includes a hydrate or a solvate thereof with a
solvent or the like. The present invention further includes
any form of crystal of the active drug of the present
invention.
[0028]
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
Examples of the pharmaceutically acceptable salts
include salts with organic bases (for example,
diethanolamine salts, ethylenediamine salts), and salts with
inorganic bases (for example, salts with alkali metals (for
5 example,
sodium, or potassium) and salts with alkaline earth
metals (for example, calcium, or magnesium).
[0029]
According to one embodiment, the compound as active
drug is preferably one or more compounds selected from the
10 following
group: a group consisting of apomorphine ((R)-(-)-
apomorphine hydrochloride), eseroline ((-)-eseroline
fumarate), ethoxyquin (6-
ethoxy-2,2,4-trimethy1-1,2-
dihydroquinoline), methyldopa (methyldopa sesquihydrate),
olanzapine (2-
methy1-4-(4-methyl-l-piperaziny1)-10H-
15
thieno[2,3-b][1,5]benzodiazepine, and indapamide (4-chloro-
N-[(2RS)-2-methy1-2,3-dihydro-1H-indo1-1-y1]-3-sulfamoyl
benzamide).
[0030]
According to one embodiment, the compound as active
20 drug is
more preferably one or more compounds selected from
the following group: a group consisting of ethoxyquin (6-
ethoxy-2,2,4-trimethy1-1,2-dihydroquinoline), and
methyldopa (methyldopa sesquihydrates).
[0031)
25 As used
herein, an "effective amount" represents an
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
36
PCT/JP2020/000538
amount of an active drug which is sufficient to provide the
desirable effect, that is, the treatment or prevention of
the retinal disease (such as age-related macular
degeneration), or the suppression of the progress of the
diseases, which are as described herein. Also the active
drug or the pharmaceutical composition of the present
invention may be used in combination with a publicly known
active drug or a pharmaceutical composition for the intended
diseases or the relevant symptoms.
[0032]
According to one embodiment, the effective amount of
the present invention may be any dose as long as it is the
dose capable of preventing an onset of the retinal disease
(such as age-related macular degeneration), treating the
symptoms of the diseases, or suppressing (improving) the
progress of the symptoms of the disease when the present
compound as active drug is administered. In the case of an
oral administration, the dose may be an orally
therapeutically effective amount, and in the case of an
intraocular administration (such as eye drop or eye ointment),
the dose may be an intraocularlly effective amount.
[0033]
The low dose as effective amount represents a dose which
is less than about one severalth to less than one a few tenth
based on the half-lethal dose of each compound, when the
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
37
PCT/JP2020/000538
present compound as an active drug is administered. For
example, the low dose represents about one fifth, preferably
about one tenth, more preferably about one twentyth, further
preferably about one fiftyth based on the half-lethal dose
of each compound, which is not be limited thereto.
Also, the dose range can be adjusted appropriately
depending on a condition including a selection of the
compound used, an administration route (for example, an oral
administration or an intraocular administration), a property
of a drug formulation, a type, age, weight or sex of a
subject, or a property of a symptom or a degree of
seriousness.
[0034]
The effective amount of the present compound is about
5% by weight or less, more preferably about 3 96 by weight or
less, even more preferably about 1 % by weight or less, and
further more preferably about 0.5 % by weight or less based
on the weight of the pharmaceutical composition for
intraocular administration, and is not limited thereto. Also
the effective amount of the present compound is about 80% by
weight or less, and more preferably about 50 % by weight or
less based on the weight of the pharmaceutical composition
for oral administration, and is not limited thereto.
[00353
Examples of the effective amount of the present compound
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
38
PCT/JP2020/000538
include about 0.001 to about 50 mg/weight kg per a daily
dose. For example, in the case of the oral administration,
the daily dose is about 0.1 to about 50 mg/kg, usually about
0.2 to about 10 mg/kg, preferably about 0.3 to about 2 mg/kg,
and more preferably about 0.4 to about 1 mg/kg, which is not
limited thereto. For example, in the case of the intraocular
administration, the daily dose is about 0.001 to about 0.1
mg/kg, usually about 0.01 to about 0.05 mg/kg, preferably
about 0.02 to about 0.05 mg/kg, and more preferably about
0.03 to about 0.05 mg/kg, which is not limited thereto. In
the case of administration with eye drop, typically about
0.5 mg/instillation per one-eye is administered in five to
six divided times per day.
The present compound or the pharmaceutical composition
of the present invention can be administered once per day,
or a plural times per day (for example, in the case of the
oral administration, they can be administered in two or three
divided times per day, and in the case of the intraocular
administration, they can be administered in two to ten
divided times, for example, five to six divided times). Also
they can be administered once or a plural times within
several days or several weeks.
10036]
As used herein, the term of "administer (or
administration)" represents that the present compound or the
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
39
PCT/JP2020/000538
pharmaceutical composition of the present invention is
provided or prescribed to an individual of subject, or the
individual receives the present compound or the
pharmaceutical composition of the present invention; and so
on. The administration route of the present compound or the
pharmaceutical composition may be either an oral
administration route or an intraocular administration route,
which can vary depending on intended disease or symptom, or
age, weight or sex of the subject, or the like, and is
preferably the intraocular administration (such as eye drop
or eye ointment) in terms of an easy of administration and
a lowering of dose and so on.
[0037]
The pharmaceutical composition of the present invention
can be administered by an oral administration route or an
intraocular administration route to the subject.
[0038]
The pharmaceutical composition of the present invention
can be prepared as the pharmaceutical composition for oral
administration or the pharmaceutical composition for
intraocular administration by using conventionally publicly
known technologies, and thereby can contain a non-toxic and
inert carrier or additive (hereinafter, referred to as
"pharmaceutically acceptable carrier") which is usually used
in the pharmaceutical field. For example, the pharmaceutical
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
composition for oral administration (oral formulations) is
formulated into, for example, tablets, fine granules,
capsules, pills, granules, powders, solutions, and
suspensions and so on, which is not limited thereto. Also
5 the pharamaceutical composition for intraocular
administration is formulated into dosage forms such as eye
drop, eye ointment, eye gel, eye cream, Tenon injectable,
and ocular fundus injectable, and so on, but which is not
limited to these forms, and eye drop or eye ointment is
10 preferably included, and eye drop is more preferably included.
[0039]
The "pharmaceutically acceptable carrier" used herein
may be contained by combining various active ingredients or
medicinal ingredients (including pharmacological active
15 ingredients or physiologically active ingredients) or
additives (for example, excipients, lubricants, binders,
disintegrants, emulsifier, stabilizer, correctives, diluents,
tonicity agents, buffer agents, pH adjusting agents,
solubilizers, thickening agents, dispersing agents,
20 preservatives (antiseptics)) in addition to the present
compound as active drug depending on various kinds of usages
such as the administration route and the dosage form as long
as a pharmacological effect is not disturbed. These
ingredients may be compounded appropriately within certain
25 concentration ranges which do not affect any irritation and
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
41
PCT/JP2020/000538
so on, and the kinds of the ingredients are not particularly
limited thereto.
[0040]
When the present compound or the pharmaceutical
composition of the present invention is used as the
pharmaceutical composition for oral administration,
pharmaceutically acceptable carriers such as excipients,
lubricants, binders, disintegrants, emulsifying agent,
stabilizer, correctives, or diluents may be contained.
[0041]
Examples of the excipients include organic excipients
and inorganic excipients. Examples of organic excipients
include one or more compounds selected from sugar derivatives
(such as lactose, sucrose, glucose, mannitol, and sorbitol),
and starch derivatives (such as corn starch, potato starch,
a-starch, and dextrin), cellulose derivatives (such as
crystalline cellulose), gum arable, dextran, prolan and the
others. Examples of the inorganic excipients include one or
more compounds selected from light anhydrous silicic acid
and sulfates (such as calcium sulfate).
[0042]
Examples of the lubricants include one or more compounds
selected from stearic acid, metal stearates (such as calcium
stearate and magnesium stearate), talc, colloidal silica,
waxes (such as bead wax), adipic acid, sulfates (such as
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
42
PCT/JP2020/000538
sodium sulfate), glycol, fumaric acid, sodium benzoic acid,
D,L-leucine, sodium lauryl sulfate, silic acids (such as
silicic acid anhydride, silicic acid hydrate), and starch
derivatives described as the above-mentioned excipients.
[0043]
Examples of the binders include one or more compounds
selected from hydroxypropyl cellulose, hydroxypropylmethyl
cellulose, polyvinylpyrrolidone, macrogol, and compounds
described as the above-mentioned excipients.
[00441
Examples of the disintegrants include one or more
compounds selected from cellulose derivatives (such as low
substituted hydroxypropyl cellulose, carboxymethyl cellulose,
calcium carboxymethyl cellulose, and internally cross-
linkedcarboxymethyl cellulose calcium), and chemically
modified starch and cellulose derivatives (such as
carboxymethyl starch, and carboxymethyl starch sodium).
[0045]
Examples of the emulsifying agents include one or more
compounds selected from colloidal clay (such as bentonite,
and Veegum), anionic surfactants (such as sodium lauryl
sulfate), cationic surfactants (such as benzalkonium
chloride), and nonionic surfactants (such as polyoxyethylene
alkyl ether, polyoxyethylene sorbitan fatty acid ester, and
sucrose fatty acid ester).
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
43
PCT/JP2020/000538
[0046]
Examples of the starbilizer include one or more
compounds selected from p-hydroxybenzoic esters (such as
methyl paraben, and propyl paraben), alcohols (such as
chlorobutanol, benzylalcohol, and phenylethyl alcohol),
phenols (such as phenol, and cresol), thimerosal, acetic
anhydride, and sorbic acid.
[0047]
Examples of the correctives include one or more
compounds selected from sweetness (such as saccharin sodium,
and aspartame), acidulants (such as citric acid, malic acid,
and tartaric acid), and fragrances (such as menthol, and
fruit extracts (such as orange extract)).
[00481
Examples of the diluents include one or more compounds
selected from lactose, mannitol, glucose, sucrose, calcium
sulfate, hydroxypropyl cellulose, microcrystalline cellulose,
water, ethanol, polyethylene glycol, propylene glycol,
glycerol, starch, and polyvinylpyrrolidone.
[0049]
When the present compound or the pharmaceutical
composition of the present invention is used as the
pharmaceutical composition for intraocular administration,
the composition may contain pharmaceutically acceptable
carriers such as tonicity agents, buffer agents, pH adjusting
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
44
PCT/JP2020/000538
agents, solubilizers, thickening agents, stabilizers,
preservatives (antiseptics), and the like.
[0050]
Examples of the tonicity agents include one or more
compounds selected from glycerin, propylene glycol, sodium
chloride, calcium chloride, sorbitol, and mannitol.
[0051]
Examples of the buffer agents include one or more
compounds selected from phosphoric acid, phosphate salt,
citric acid, acetic acid, and E-amino caproic acid.
[0052]
Examples of the pH adjusting agents include one or more
compounds selected from hydrochloric acid, citric acid,
phosphoric acid, acetic acid, sodium hydroxide, calcium
hydroxide, boric acid, borax, sodium hydrogen phosphate,
sodium dihydrogen phosphate, sodium carbonate, and sodium
hydrogencarbonate. The pH of the eye drop may be within a
range which is acceptable as eye formulations, and preferably,
it is usually adjusted to pH 4.0 to 8.5.
[0053]
Examples of the solubilizers include one or more
compounds selected from polysorbate 80, polyoxyethylene
hardened castor oil 60, or macrogol 4000.
[0054]
Examples of the thickening agents and dispersing agents
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
include one or more compounds selected from cellulose polymer
(such as hydroxypropyl methyl cellulose, and hydroxypropyl
cellulose), polyvinyl alcohol, or polyvinylpyrrolidone.
[0055]
5 Examples
of the stabilizers include one or more
compounds selected from edetic acid and sodium edetate.
[0056]
Examples of the preservatives (antiseptics) include one
or more compounds selected from sorbic acid, potassium
10 sorbate, benzalkonium chloride, benzethonium chloride,
methyl paraoxybenzoate, propyl paraoxybenzoate, Or
chlorobutanol.
[0057]
The pharmaceutical composition, the eye drop, or the
15 oral drug
of the present invention may further contain one
or more compounds for increasing efficacies. Examples of
such a compound may include antibiotics, steroids, anti-
inflammatory agents, analgesic agents, surfactants,
chelating agents, buffer agents, pH adjusting agents, or
20
adjuvants, or any combinations of two or more of them, and
which is not be limited to these agents. Specific examples
of the compounds in the case of eye drop may include vitamin
C source, vitamin E source, vitamin A source, beta-carotene,
zinc source, or copper source, or any combinations of two or
25 more of
these compounds, and which is not be limited to these
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
46
PCT/JP2020/000538
agents.
[0058]
According to one embodiment, the eye drop of the present
invention is a sterilized type of unit dosage form not
containing a preservative. Also according to one embodiment,
the eye drop of the present invention is an eye drop which
does not substantially contain benzalkonium chloride.
[0059]
When the pharmaceutical composition of the present
invention is used as an intraocular adminisitration
formulation (such as eye drop), as needed, any compounds for
increasing efficacies may be contained as long as an eye
pain is caused, and examples of the compounds include anti-
inflammatory drugs (such as epsilon aminocaproic acid, and
diclofenac sodium), vasoconstrictor (such as
tetrahydrozoline hydrochloride, and
phenylephrine
hydrochloride), antiallergic drug (such as sodium
cromoglicate, and ketotifen fumarate), antihistamine drug
(such as chlorpheniramine maleate, and diphenhydramine
hydrochloride), or vitamins (such as riboflavin phosphate,
cyanocobalamin, and panthenol), and which is not be limited
to these compounds.
EXAMPLES
[0060]
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
47
PCT/JP2020/000538
The present invention is more specifically explained by
the Formulation Examples and Test Examples as follows, and
the present invention is not limited to these examples. The
compounds, the mice, and the reagents which are used in the
Examples were available from commercial sources, or were
prepared according to publicly known methods.
[0061]
Formulation Examples
The Formulation examples of the pharmaceutical
composition of the present invention are shown below, and
are not limited thereto.
[0062]
(Formulation Example 1)
Tablet
[Table 1]
In 100 mg
Methyldopa 25 mg
Lactose 49.5 mg
Corn starch 11 mg
Carboxymethyl cellulose calcium 7 mg
Hydroxypropyl cellulose 7 mg
Magnesium stearate 0.5 mg
A tablet is prepared by a generally known formulating
method of a tablet. Specifically, methyldopa as the present
compound, corn starch, and lactose are mixed in a mixer, and
carboxymethyl cellulose calcium, and hydroxypropyl cellulose
are added to the mixture, and the mixture is granulated, and
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
48
PCT/JP2020/000538
the resulting granules are subjected to a grain size
procedure after drying, and magnesium stearate is added to
the granules with grained size, and mixed with each other,
and the mixture is compressed with a tableting machine. Also
by changing an addition amount of the present compound,
certain tablets containing a desirable amount of the present
compound (such as 10 mg, 25 mg, or 50 mg) in a 100 mg tablet
can be prepared.
[0063]
(Formulation Example 2)
Eye Drop
[Table 2]
In 100 mL
Methyldopa 500 mg
Sodium chloride 1000 mg
Polysorbate 80 appropriate
Sodium hydrogen phosphate appropriate
Sodium dihydrogen phosphate appropriate
Sterile purified water appropriate
An eye drop is prepared by a generally known formulating
method of an eye drop. Specifically, into a sterile purified
water, methyldopa as the present compound, and the above-
mentioned ingredients other than methyldopa are added, and
the mixture is mixed well to prepare a solution for eye drop.
By changing an addition amount of the present compound such
as methyldopa, certain eye drops containing a desirable
amount of the present compound (such as 0.3 t (W/V), 0.5 96
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
49
PCT/JP2020/000538
or 1 % (W/V)) in a 100 mL eye drop can be prepared.
[0064]
(Formulation Example 3)
Eye Ointment
[Table 3]
In 100 g
Methyldopa 0.3g
Liquid paraffin 10.0 g
white petrolatum Appropriate
An eye ointment is prepared by a generally known
formulating method of an eye ointment. Specifically, into
white petrolatum and liquid paraffin which are homogeneously
melted, methyldopa as the present compound is added, and the
mixture is mixed well, and afterthat, the resulting mixture
is cooled gradually to prepare an eye ointment. By changing
an addition amount of the present compound such as methyldopa,
certain eye intments containing a desirable cncetration of
the present compound (such as 0.3 % (W/W), 0.5 % (W/W), or
1 t (W/W)) in a 100 g eye ointment can be prepared.
[0065]
(Test Example 1)
Pharmacological Test against age-related macular
degeneration (AMID) (Oral administration)
The pharmacological activity (AMID) of the test compound
against age-related macular degeneration (AND) was examined.
The test compounds are indicated below.
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
ethoxyquin (Compound X), eseroline (Compound W),
methyldopa (Compound Y), and indapamide (Compound A).
A test was performed using a light irradiation model,
which is widely employed as an atrophic AND model mouse, as
5 a test model.
[0066]
(Procedures)
First, AND model mice were produced according to the
following schedule.
10 Laboratory animals
Male BALB/c mice (4 weeks old) were purchased from Japan
SLC, Inc., and allowed to acclimate for a week before being
used for experiments. Laboratory animal chow (CLEA Rodent
Diet CE-2, CREA JAPAN, INC.) was used as food, and tap water
15 was freely consumed as drinking water. The animals were
raised under light and dark cycles of every 12 hours. Also
all animal experiments were conducted under the approval of
the Kyushu University Animal Experiment Committee.
[0067]
20 Production of light-induced AND model mice
Amethod for producing age-related macular degeneration
(AND) model mice (production schedule) is shown in Figure 1.
To BALB/c mice, 1 mL/kg of 50 pM compound dissolved in
PBS containing 10% polyethylene glycol (PEG) 300 was orally
25 administered. Thirty (30) minutes later, one drop of Midrin
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
51
PCT/JP2020/000538
P (5 mg/mL tropicamide, 5 mg/mL phenylephrine hydrochloride;
Santen Pharmaceutical Co., Ltd.) was applied to each eye as
a mydriatic drug. The mice were irradiated with 8000 lux
white light for 10 hours, then returned to under normal light
and dark cycles, and raised for 6 days. On day 7, the animal
was euthanized by cervical dislocation, and the eyeballs
were removed (Figure (1a)).
[0068]
Preparation of frozen eyeball section
Frozen sections of 8 pm thickness were prepared by using
the above-mentioned removed eyeballs, and subjected to
hematoxylin eosin (HE) staining, and the thickness of the
outer nuclear layer (ONL) was measured over 27 points every
180 pm (observation magnification: 60 times) (Figure 1 (b)).
[0069]
HE staining
The preparation was air-dried for 1 hour, fixed with
acetone at room temperature for 15 minutes, then immersed in
99.5% Et0H, 80% Et0H, 70% Et0H, and purified water in this
order for 3 minutes each, and stained with hematoxylin for
10 minutes. Then, it was washed with running water for 10
minutes, soaked in warm water for 1 minute, and stained with
eosin for 1.5 minutes. After washing with purified water,
it was immersed in 70% Et0H, 80% Et0H, and 99.5% Et0H in
this order for 3 minutes each, then washed with xylene three
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
52
PCT/JP2020/000538
times, dried, and then enclosed with VectaMount (TM) Mounting
Medium. The
resultant was subjected to observation and
imaging with Keyence fluorescence microscope (BZ-9000).
[0070]
Statistical analysis
Results were expressed as mean+standard deviation.
Dunnett's Test was used for multigroup comparison.
[0071]
(Results)
The imaging results in which the thickness of an outer
nuclear layer was evaluated are shown in Figure 2. In the
case of the dose of 50 pmol/kg, the results of the ONL bright
field image (observation magnification: 60 times) (Figure
2(a)) and the mean thickness of the ONL (Figure 2(b)) of the
present compounds (ethoxyquin (Compound X), eseroline
(Compound W), methyldopa (Compound li), and indapamide
(Compound A)), compared to a control and control compounds
(Edaravone, OT-551 (4-cyclopropylcarboxy-1-hydroxy-2,2,6,6-
tetramethyl-pyperidine) were obtained. The
Figure 2(a)
includes an inner nuclear layer (INL) in the top, an outer
nuclear layer (ONL) in the middle, and a retinal pigment
epithelium (RPE) in the bottom. When cell death occurs due
to lipid peroxidation, the thickness of the outer nuclear
layer in the middle becomes thinner.
First, the thickness of ONL was significantly reduced
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
53
PCT/JP2020/000538
by light irradiation (Figure 2(a) negative control). The
extent of ONL disorders was particularly severe on the
superior side of the eyeball, and these results were
consistent with the results known from the literature (see,
for example, Tanito M., et al., Invest. Ophthalmol. Vis.
SCI., 2007, 48 (4), 1900-5.).
On the other hand, in the case of the four present
compounds used in this study, the ONL thickness in either
case did not differ so much compared to that of the positive
control. Significant thicknesses were observed compared to
that of Edaravone and OT-551 as control compounds even at
the same dose of 50 pmol/kg, and in particular, in the case
of ethoxyquin (Compound X) and indapamide (Compound A), the
thickness that was not different so much compared to that of
the positive control was observed (Figure 2(b)).
Further, in the case of the dose of 100 pmol/kg or 200
pmol/kg, the results of the ONL bright field image
(observation magnification: 40 times) (Figure 2(c)) and the
mean thickness of the ONL (Figure 2(d)) of the present
compound (methyldopa (Compound Y)), compared to a control
were obtained. The thickness of the ONL of this case didn't
have significant difference compared to that of the positive
control (Figure 2(c)). Also the thickness that was not
different so much as compared to that of the positive control
was observed (Figure 2(d)).
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
54
PCT/JP2020/000538
[0072]
For OT-551, which is a compound known to have a high
retinal protective effect, approximately 100 mg/kg (360
pmol/kg) of the compound has been reported to be required in
a light irradiation model mouse. Thus, the dose 50 pmol/kg
in this study, about one-seventh of that of OT-551, is a
considerably low dose.
In addition, 50 pmol/kg is less than one-tenth of each
median lethal dose (LD50) of the five test compounds, thus
the compounds have been confirmed to be safe (see Figure 5).
[0073]
(Test Example 2)
Pharmacological Test against age-related macular
degeneration (AND) (Administration by eye drop)
The pharmacological activity of the test compound
against age-related macular degeneration (AND) was examined.
The present compound as a test compound was methydopa
(Compound Y).
A test was performed using a light irradiation model,
which is widely employed as an atrophic AND model mouse, as
a test model.
[0074]
(Procedures)
First, AND model mice were produced according to the
following schedule.
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
Laboratory animals
Male BALB/c mice (4 weeks old) were purchased from Japan
SLC, Inc., and allowed to acclimate for a week before being
used for experiments. Laboratory animal chow (CLEA Rodent
5 Diet CE-2, CREA JAPAN, INC.) was used as food, and tap water
was freely consumed as drinking water. The animals were
raised under light and dark cycles of every 12 hours. Also
all animal experiments were conducted under the approval of
the Kyushu University Animal Experiment Committee.
10 [0075]
Production of light-induced AND model mice
A method for producing age-related macular degeneration
(AND) model mice (production schedule) is shown in Figure 3.
To BALE/c mice, Midrin P (5 mg/mL tropicamide, 5 mg/mL
15 phenylephrine hydrochloride; Santen Pharmaceutical Co.,
Ltd.) as a mydriatic drug was applied to both eyes by one
drop per one eye, and after 10 minutes, 0.45 %, 0.75 % or
1 % of methyldopa that was dissolved in PBS containing 10 %
polyethylene glycol (PEG) 300 was administered with eye drop
20 in 50 pL of the compound per one eye. Thereafter, the mice
were irradiated with 8000 lux white light for 10 hours, then
returned to under normal light and dark cycles, and raised
for 6 days. On day 7, the animal was euthanized by cervical
dislocation, and the eyeballs were removed.
25 [0076]
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
56
PCT/JP2020/000538
Preparation of frozen eyeball section
Frozen sections of 8 pm thickness were prepared by using
the above-mentioned removed eyeballs, and subjected to
hematoxylin eosin (HE) staining, and the thickness of the
outer nuclear layer (ONL) was measured over 27 points every
180 lou (observation magnification: 40 times).
[0077]
HE staining
The preparation was air-dried for 1 hour, fixed with
acetone at room temperature for 15 minutes, then immersed in
99.5% Et01-{, 80% Et0H, 70% Et0H, and purified water in this
order for 3 minutes each, and stained with hematoxylin for
10 minutes. Then, it was washed with running water for 10
minutes, soaked in waim water for 1 minute, and stained with
eosin for 1.5 minutes. After washing with purified water,
it was immersed in 70% Et0H, 80% Et0H, and 99.5% Et0H in
this order for 3 minutes each, then washed with xylene three
times, dried, and then enclosed with VectaMount (TM) Mounting
Medium. The resultant was subjected to observation and
imaging with Keyence fluorescence microscope (BZ-9000).
[0078]
Statistical analysis
Results were expressed as mean+standard deviation.
Dunnett's Test was used for multigroup comparison.
[0079)
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
57
PCT/JP2020/000538
(Results)
The imaging results in which the thickness of an outer
nuclear layer was evaluated are shown in Figure 4. The
results of the ONL bright field image (observation
magnification: 40 times) (Figure 4(a)) and the mean thickness
of the ONL (Figure 4(b)) of the present compound (methyldopa
(Compound Y)) compared to a control were obtained. The
Figure 4(a) includes an inner nuclear layer (INL) in the top,
an outer nuclear layer (ONL) in the middle, and a retinal
pigment epithelium (RPE) in the bottom. When cell death
occurs due to lipid peroxidation, the thickness of the outer
nuclear layer in the middle becomes thinner.
First, the thickness of ONL was significantly reduced
by light irradiation (Figure 4(a) negative control). The
extent of ONL disorders was particularly severe on the
superior side of the eyeball, and these results were
consistent with the results known from the literature (see,
for example, Tanito M., et al., Invest. Ophthalmol. Vis.
SCI., 2007, 48 (4)1 1900-5.).
On the other hand, in the case of methyldopa as the
present compound used in this study, when the concentration
of the compound in eye drop was 0.45 %, 0.75 % or 1 %, the
ONL thickness in either case had significant thickness
compared to that of the light irradiation case, and in
particular, when the concentration of the compound was 0.75 %
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
58
PCT/JP2020/000538
or more (0.75 % and 1 %), significant difference due to the
difference of the concentration was not observed (Figure
4(b)).
[0080]
Here the dose of the present compounds in the case of
administration with the eye drop used in Test Example 2
described herein is a considerably low dose compared as the
dose of the test compound in the case of oral administration
used in Test Example 1 described herein. Accordingly, the
dose of this case was confirmed to be remarkably low compared
to the above-mentioned half lethal dose of the present
compounds, and the present compounds have been thus confirmed
to be safe.
[0081]
From the above results, it is suggested that the present
compound or the pharmaceutical composition of the present
invention shows superior therapeutic activity against age-
related macular degeneration in the case of intraocular
administration (in partiuclar, eye drop) or oral
administration, in particular intraocular administration (in
partiuclar, eye drop).
[0082]
(Test Example 3)
Activity evaluation test of Muller cell
For age-related macular degeneration (AMD), the
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
59
PCT/JP2020/000538
suppression activity of the test compounds against the
expression amount of mRNA of a marker protein, which is used
as an indicator of activity of Muller cell and is increased
as a pathology is deteriorated, was examined. The present
compound as test compound was methyldopa (Compound Y).
[0083]
(Procedures)
First, AND model mice were produced according to the
following schedule.
Laboratory animals
Male EALB/c mice (4 weeks old) were purchased from Japan
SLC, Inc., and allowed to acclimate for a week before being
used for experiments. Laboratory animal chow (CLEA Rodent
Diet CE-2, CREA JAPAN, INC.) was used as food, and tap water
was freely consumed as drinking water. The animals were
raised under light and dark cycles of every 12 hours. Also
all animal experiments were conducted under the approval of
the Kyushu University Animal Experiment Committee.
[0084]
Production of light-induced AMD model mice
A method for producing age-related macular degeneration
(AND) model mice (production schedule) was prepared
according to the method described in Test Example 2 (Figure
3).
Specifically, to 9 week olds of BALE/c mice, 1 mL/kg of
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
SO pM test compounds dissolved in PBS containing 10%
polyethylene glycol (PEG) 300 was orally administered. A
PBS solution containing 10% polyethylene glycol (PEG) 300
was used as a control. Thirty (30) minutes later, one drop
of Midrin P (5 mg/mL tropicamide, 5 mg/mL phenylephrine
hydrochloride; Santen Pharmaceutical Co., Ltd.) as a
mydriatic drug was applied to both eyes by one drop per one
eye. The mice were irradiated with 8000 lux white light for
10 hours, then returned to under normal light and dark cycles,
10 and raised for the desirable observation periods. After the
observation periods, the animal was euthanized by cervical
dislocation, and the retina were removed.
[0085]
Real-time PCR method
15 For the removed retina, RNA was extracted by using
ISOSPIN Cell & Tissue RNA (manufactured by Nippon Gene Co.
Ltd), and cDNA was then synthesized by using ReverTra Ace
(TM) qPCR RT master mix (manufactured by Toyobo Co. Ltd).
The obtained cDNA was diluted with sterile water to 0.5 ng4L,
20 and a real-time PCR was carried out with THUNDERBIRD (TM)
SYBR (TM) qPCR Mix (manufactured by Toyobo Co. Ltd). All of
the test results were corrected by Gapdh mRNA amounts, and
a relative quantification was carried. The primer sequences
that were used for each gene are shown in Table 4 below.
25 [0086]
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
61
PCT/JP2020/000538
(Results)
The test results are shown in Figure 6. It is shown in
Figure 6A a change of expression amounts of mRNA of Muller
cell marker protein in a normal group of mice and a
pathological group of mice in the case of not administrating
with any test compound. It is shown in Figure 6B a change
of expression amounts of mRNA of Muller cell marker protein
in a normal group of mice, a pathological group of mice in
the case of not administrating with any test compound, and
a pathological group of mice in the case of administrating
with any test compound.
As shown in Figure 6A, the mice of the pathological
group showed an increase in expression amounts of mRNA
compared to the mice of the normal group. On the other hand,
as shown in Figure 6B, when test compounds were administered
to the mice in the pathological group, it was observed the
remarkable suppression of the mRNA expression amounts
wherein the remarkable increase in expression amounts of
mRNA was observed in Figure 6A.
From these results, it was found that methyldopa as the
present compound can suppress significantly the increase in
expression amounts of mRNA in Muller cell marker protein
which is related to age-related macular degeneration.
[0087]
(Test Example 4)
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
62
PCT/JP2020/000538
Activity evaluation test of Microglia
For age-related macular degeneration (AND), the
suppression activity of the test compounds against the
expression amount of mRNA of a marker protein, which is used
as an indicator of activity of Muller cell and is increased
as a pathology is deteriorated, was examined. The present
compound as test compound was methyldopa (Compound Y).
[0088]
(Procedures)
First, experimental procedures for the production
process of the test model mice, and the real-time PCR method
were carried out by the method described in Test Example 3.
[00891
(Results)
The test results are shown in Figure 7. It is shown in
Figure 7A a change of expression amounts of mRNA of microglia
marker protein in a normal group of mice, and a pathological
group of mice in the case of not administrating with any
test compound. It is
shown in Figure 7B a change of
expression amounts of mRNA of microglia marker protein in a
normal group of mice, a pathological group of mice in the
case of not administrating with any test compound, and a
pathological group of mice in the case of administrating
with any test compound.
As shown in Figure 7A, the mice of the pathological
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
63
PCT/JP2020/000538
group showed an increase in expression amounts of mRNA
compared to the mice of the normal group. On the other hand,
as shown in Figure 7E, when test compounds were administered
to the mice in the pathological group, it was observed the
remarkable suppression of the mRNA expression amounts
wherein the remarkable increase in expression amounts of
mRNA was observed in Figure 7A.
From these results, it was found that methyldopa as the
present compound can suppress significantly the increase in
expression amounts of mRNA in microglia marker protein which
is related to age-related macular degeneration.
[0090]
The sequences of the primer that were used in the real-
time PCR method that was carried in the Test Examples as
described herein are shown in Table 4.
Table 4. Sequence of Primer used in Test Examples as
described herein
[Table 4I
Name Primer Sequence SEQ ID No.
Vimentin Forward 5'-CCITGACATTGAGATTGCCA-3' _ SEQ ID No, 22
Reverse 5'-GTATCAACCAGAGGGAGTGA-3' SEQ ID No. 23
GFAP Forward 5'-AAGACACTGTGGCTCGTC-3' SEQ ID No. 24
Reverse 5'-CTTCCTGTAGGTGGCAAT-3' SEQ ID No. 25
GS Forward 5r-CCAACAAGCTGGTGCTATGTGAA-3 SEQ ID No. 26
Reverse 5t-CTGGTTGCTCACCATGTCCA SEQ ID No. 27
EAAT I Forward 5`-AATGTGGTATGCGCCTCTOG-3' SEQ ID No. 28
Reverse 5'-GCAGCAACCCTCCAATGAAA-3' SEQ ID No. 29
EAAT2 Forward 5'-GTGGCACCTCCATCTGAGGA-3' SEQ ID No. 30
_ Reverse 5'-CACCATCAGCTTGGCCTGTT-3' SEQ ID No. 10
Iba I Forward 5.-GTCCITGAAGCGAATGCTGG-3' SEQ ID No. 1
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
64
PCT/JP2020/000538
Reverse .5"-CATTCTCAAGATGGCAGATC-3' _ SEQ
ID No. 12
CD68 Forward 5'-
CTCTCTAAGGCTACAGGCTGCT-3' SEQ ID No. 13
Reverse 5'-TCACGGTTGCAAGAGAAACA-3' SEQ ID
No. 14
CD1lb Forward 5'-GTGTGACTACAGCACAAGCCG-3' SEQ ID
No. 15
Reverse 5'-
CCCAAGGACATATTCACAGCCT-3' SEQ ID No. 16
TSPO Forward 5' -TGCAGAAACCCTCTTGGCATC-3' SEQ ID
No. 17
Reverse 5'-TGAAACCTCCCAGCTCTTTCC-3' SEQ ID
No. 18
Arnwap Forward 5'-TTTGATCACTGTGGGGATGA-3' SEQ ID
No. 19
Reverse 5'-ACACTTTCTGGTGAAGGCTTG-3' SEQ ID
No. 20
F4/80 Forward 5'-TGGAAGTGGATGGCATAGATG-3' SEQ ID
No. 21
Reverse 75'-TTCACTGTCTGCTCAACG-3' SEQ ID
No. 22
cis Forward 5' -CCCTGTAGCCACTTCTGCAA-3' SEQ ID
No. 23
Reverse 5'-GGGCAGTGAACACATCTCCA-3' SEQ ID
No. 24
c4 Forward 5'-TCTGAAGCCTCCAACGTTCC-3' - SEQ
ID No. 25
Reverse 5"-TGGGATGGGGAAGGAAATGC-3' SEQ ID
No. 26
cfb Forward 5'-GAAACCCTGTCACTGTCATTC-3' SEQ ID
No. 27
Reverse 5'-CCCCAAACACATACACATCC-3' SEQ ID
No. 28
cfd Forward 5' -CTGGGAGCGGCTGTATGT-3' SEQ ID
No. 29
Reverse - 5'-CACGGAAGCCATGTAGGG-3' SEQ ID
No. 30
c3 Forward 5'-AGCCCAACACCAGCTACATC-3' SEQ ID
No. 31
Reverse - 5'-GAATGCCCCAAGTiCTTCGC-3' SEQ ID
No. 32
c5 Forward 5'-CAGCAAGGAGGAGTCAACAT-3' SEQ ID
No. 33
Reverse 5'-TCCACAAGAGCCCGTAAATC-3 SEQ ID
No. 34
c9 Forward 5'-TGGTGACAACGACTGIGGAG-3' _ SEQ
ID No. 35
Reverse 5'-TGTTGATCCCATAGCCTGCTG-3' SEQ ID
No. 36
cfh Forward 5'-GTGGGCATCCCGGAGAC-3' SEQ ID
No. 37
Reverse 5'- SEQ ID
No. 38
CACCAAACTCAAATTGAGATCCAA-3'
Gapdh Forward 5'-
AATGTGTCCGTCGTGGATCTGA-3' SEQ ID No. 39
Reverse 5'-GATGCCTGCTTCACCACCTICT-3' SEQ ID
No. 40
[ 0 0 91]
(Test Example 5)
Activity evaluation test of Complement
For age-related macular degeneration (AND), the
suppression activity of the test compounds against the
expression amount of mRNA of a complement, which is increased
as a pathology is deteriorated, was examined. The present
compound as test compound was methyldopa (Compound Y).
[0092]
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
PCT/JP2020/000538
(Procedures)
Experimental procedures for the production process for
the test model mice, and the real-time PCR method were
carried out by the method described in Test Example 3.
5 [0093]
(Results)
The test results are shown in Figure 8. It is shown in
Figure 87 a change of expression amounts of mRNA of a
complement in a normal group of mice, and a pathological
10 group of
mice in the case of not administrating with any
test compound. It is
shown in Figure 8B a change of
expression amounts of mRNA of a complement in a normal group
of mice, a pathological group of mice in the case of not
administrating with any test compound, and a pathological
15 group of
mice in the case of administrating with any test
compound.
As shown in Figure 8A, the mice of the pathological
group showed an increase in expression amounts of mRNA
compared to the mice of the normal group. On the other hand,
20 as shown
in Figure 8B, when test compounds were administered
to the mice in the pathological group, it was observed the
remarkable suppression of the mRNA expression amounts
wherein the remarkable increase in expression amounts of
mRNA was observed in Figure 8A.
25 From
these results, it was found that methyldopa as the
Date Recue/Date Received 2021-07-09
CA 03126333 2021-07-09
66
PCT/JP2020/000538
present compound can suppress significantly the increase in
expression amounts of mRNA in the complement which is related
to age-related macular degeneration.
[Industrial Applicability]
[0094]
The present compound or the pharmaceutical composition
of the present invention is useful as pharmaceuticals for an
intraocular administration or an oral administration for
treatment and the like of retinal diseases (such as age-
related macular degeneration).
[Free Text of Sequence Listing]
[0095]
SEQ ID NOs: 1 to 40 each represents a PCR primer.
Date Recue/Date Received 2021-07-09
